Plain-English translation of NCT07097142 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
The ARCHER trial is testing whether patients with muscle-invasive bladder cancer can be treated effectively with a much shorter course of radiation therapy (just 5 treatments over 1–2 weeks) instead of the standard 20 treatments over 4 weeks — all while receiving chemotherapy. Researchers believe the newer, more concentrated radiation approach may work just as well while potentially causing fewer side effects and being easier on patients.
Standard radiation therapy for bladder cancer takes 4 weeks and can be difficult for patients to tolerate, with significant side effects on the bladder and bowel. This trial exists to see whether newer radiation technology can deliver the same cancer-fighting results in much less time, which could improve patients' quality of life and make treatment more accessible.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you'll be randomly assigned to receive either the standard 20 radiation treatments over 4 weeks or the newer 5 radiation treatments over 1–2 weeks — both combined with chemotherapy given by your doctor's choice of regimen. You'll have imaging scans (CT, MRI, or PET) throughout the study to monitor your progress, and you may be asked to provide optional blood and urine samples to help researchers understand how the cancer responds. Follow-up visits will continue after treatment to check for side effects and watch for any signs of cancer recurrence.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States